These are the first 10 drugs subject to Medicare price negotiations

The Biden administration unveiled Tuesday the names of the first 10 drugs subject to price negotiations in Medicare.

They are: Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, and Fiasp and certain other insulins made by Novo Nordisk, including NovoLog.

Once set, the negotiated prices take effect in 2026 – though the drug industry has filed multiple lawsuits seeking to derail the effort.

This story is breaking and will be updated.